- Home
- NNBR vs ACTU Comparison
NNBR vs ACTU Comparison
Compare NNBR & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- ACTU
- Stock Information
- Founded
- NNBR 1980
- ACTU 2015
- Country
- NNBR United States
- ACTU United States
- Employees
- NNBR N/A
- ACTU N/A
- Industry
- NNBR Industrial Machinery/Components
- ACTU
- Sector
- NNBR Industrials
- ACTU
- Exchange
- NNBR Nasdaq
- ACTU NYSE
- Market Cap
- NNBR 149.8M
- ACTU 135.0M
- IPO Year
- NNBR 1994
- ACTU 2024
- Fundamental
- Price
- NNBR $1.70
- ACTU $8.00
- Analyst Decision
- NNBR
- ACTU Strong Buy
- Analyst Count
- NNBR 0
- ACTU 1
- Target Price
- NNBR N/A
- ACTU $20.00
- AVG Volume (30 Days)
- NNBR 177.5K
- ACTU 42.0K
- Earning Date
- NNBR 05-05-2025
- ACTU 05-21-2025
- Dividend Yield
- NNBR N/A
- ACTU N/A
- EPS Growth
- NNBR N/A
- ACTU N/A
- EPS
- NNBR N/A
- ACTU N/A
- Revenue
- NNBR $464,290,000.00
- ACTU N/A
- Revenue This Year
- NNBR $0.82
- ACTU N/A
- Revenue Next Year
- NNBR $6.29
- ACTU N/A
- P/E Ratio
- NNBR N/A
- ACTU N/A
- Revenue Growth
- NNBR N/A
- ACTU N/A
- 52 Week Low
- NNBR $1.69
- ACTU $5.51
- 52 Week High
- NNBR $4.67
- ACTU $11.73
- Technical
- Relative Strength Index (RSI)
- NNBR 27.23
- ACTU N/A
- Support Level
- NNBR $1.58
- ACTU N/A
- Resistance Level
- NNBR $2.00
- ACTU N/A
- Average True Range (ATR)
- NNBR 0.21
- ACTU 0.00
- MACD
- NNBR -0.03
- ACTU 0.00
- Stochastic Oscillator
- NNBR 13.64
- ACTU 0.00
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets. It also operates in China, Mexico, Brazil, Germany, and other countries.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.